Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

Clinical trial NCT03066258 · COMPLETED

Trial details

NCT number: NCT03066258
Sponsor: REGENXBIO Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neovascular Age-related Macular Degeneration Wet Age-related Macular Degeneration

Start date: 2017-03-29
Primary completion: 2019-11-24
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.